Palladia, 10 mg, 30 Tablets

Palladia, 10 mg, 30 Tablets for Dogs

Palladia, a multi-kinase inhibitor, is indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs. Palladia is a canine cancer therapy with antiangiogenic and antiproliferative effects.

DIRECTIONS: Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of Palladia for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. Palladia may be administered with or without food. Do not split tablets.

CAUTIONS & WARNINGS: Palladia may cause vascular dysfunction which can lead to edema and thromboembolism, including pulmonary thromboembolism. Discontinue drug until clinical signs and clinical pathology have normalized. To assure vasculature homeostasis, wait at least 3 days after stopping drug before performing surgery.

INGREDIENTS: Toceranib Phosphate.

This product requires a prescription.

All prescription items are Non-Refundable and Non-Returnable.

View manufacturer and/or label information